Vutrisiran Receives EU Approval for hAATR Amyloidosis Vutrisiran Receives EU Approval for hAATR Amyloidosis

The RNAi therapeutic vutrisiran has been approved by the European Commission for hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy on the basis of the phase 3 HELIOS-A trial.International Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news